

I find

In Re Application of: **Smeyne et al.**

JUL 24 2006

Filing Date

December 12, 2003

Examiner

MAILED
Steven H. Standley

Customer No.

28,172

Group Art Unit

1649

Confirmation No.

2530

Title: Method for Determining Sensitivity to Environmental Toxins and Susceptibility to Parkinson's Disease

(Only complete if Applicant elects to pay the fee set forth in 37 CFR 1.17(p))

- ☐ A check in the amount of _____ is attached.
- ☒ The Director is hereby authorized to charge and credit Deposit Account No. 50-0858
as described below.
- ☐ Charge the amount of _____
- ☒ Credit any overpayment.
- ☒ Charge any additional fee required.
- ☐ Payment by credit card. Form PTO-2038 is attached.

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

Certificate of Mailing by First Class Mail

(Date)

Signature

Typed or Printed Name of Person Signing Certificate

(Date)

Signature of Person Mailing Correspondence

Terri Warner

Typed or Printed Name of Person Mailing Certificate

***This certificate may only be used if paying by deposit account.**

Dated:

Signature

P10A/REV05

STATEMENT UNDER 37 CFR 1.97(e) ACCOMPANYING
INFORMATION DISCLOSURE STATEMENT

Docket No.
023868.43877

In Re Application Of: Smeyne et al.

Application No.

10/734,372

Filing Date

12/12/2003

Examiner

Steven H. Standley

Customer No.

28,172

Group Art Unit

1649

Confirmation No.

2530

Invention:

Method for Determining Sensitivity to Environmental Toxins and Susceptibility to Parkinson's Disease

COMMISSIONER FOR PATENTS:

This is a statement under the provisions of 37 CFR 1.97(e) in the above-identified application.


Check applicable statement herebelow:

Statement Under 37 CFR 1.97(e)(1)

- ☒ Each item of information contained in the accompanying Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the Information Disclosure Statement.

Statement Under 37 CFR 1.97(e)(2)

- ☐ No item of information contained in the accompanying Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the undersigned person, after making reasonable inquiry, no item of information contained in the accompanying Information Disclosure Statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of the Information Disclosure Statement.


Signature

Dated:

7/21/04

Certificate of Mailing by First Class Mail

I certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to "Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450" [37 CFR 1.8(a)] on

7/21/06
(Date)



Signature of Person Mailing Correspondence

TERRI WARNER

Typed or Printed Name of Person Mailing Correspondence

cc:

INFORMATION DISCLOSURE CITATION <i>(Use several sheets if necessary)</i>				ATTY DOCKET NO. 023868.43877		APPLICATION NO. 10/734,372	
				APPLICANT(S) Smeyne et al.			
				FILING DATE December 12, 2003		GROUP ART UNIT 1649	

JUL 24 2006
 PATENT & TRADEMARK OFFICE

U.S. PATENT DOCUMENTS							
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	AA	6,204,248	03/20/2001	Demopoulos et al.	514	21	12/09/1999

U.S. PATENT APPLICATION PUBLICATIONS							
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE


FOREIGN PATENT DOCUMENTS								
		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO

OTHER DOCUMENTS <i>(Including Author, Title, Date, Pertinent Pages, Etc.)</i>			
		BB	Awashi, Yogesh C. et al., MPTP Metabolites Inhibit Rat Brain Glutathione S-Transferases
		CC	Lidor, Yaron J. et al., Alkylating Agents and Immunotoxins Exert Synergistic Cytotoxic Activity Against Ovarian Cancer Cells; Mechanism of Action

EXAMINER	DATE CONSIDERED
----------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

INFORMATION DISCLOSURE CITATION <i>(Use several sheets if necessary)</i>				ATTY DOCKET NO. 023868.43877		APPLICATION NO. 10/734,372	
				Smeyne et al.			
				FILING December 12, 2003		GROUP ART 1649	



U.S. PATENT DOCUMENTS							
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

U.S. PATENT APPLICATION PUBLICATIONS							
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS								
		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO

OTHER DOCUMENTS <i>(Including Author, Title, Date, Pertinent Pages, Etc.)</i>			
		DD	Marionnet, D. et al., Modulation of Drug-Metabolizing Systems by Bacterial Endotoxin in Carp Liver and Immune Organs
		EE	Perry, Thomas L. et al., Idiopathic Parkinson's Disease, Progressive Supranuclear Palsy and Glutathione Metabolism in the Substantia Nigra of Patients

EXAMINER	DATE CONSIDERED
----------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.